Back to Peptides

Vesilute

Moderate Research

ED Dipeptide | Bladder & Urinary Tract Bioregulator

Dose 10-20 mg per day
Frequency Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Cycle 10-20 day cycle
Storage Lyophilized powder: room temperature or 2-8°C; Reconstituted: 2-8°C refrigerated, use within 4 weeks

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.

Mechanism of Action

Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.

Key Benefits

  • Supports bladder and urinary tract function
  • May improve prostate health in men
  • Regulates smooth muscle function
  • Enhances pelvic tissue blood flow
  • Supports cellular regeneration
  • Part of comprehensive Khavinson bioregulator protocols
  • Well-tolerated in research
  • Oral bioavailability as small dipeptide
Molecular Weight
262 Da
Chain Length
2 amino acids
Type
Dipeptide bioregulator
Amino Acid Sequence
One-letter: E?
H₂N
E 1
O ‖ C
N
H
? 2
COOH
Glu
1

Glutamic Acid

Position 1

Asp
2

Asp (ED)

Position 2

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Urinary Tract Health

  • Bladder Function Support

    Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.

  • Urinary Tract Health

    May support overall urinary tract function and tissue health.

  • Pelvic Floor Support

    Potential benefits for pelvic tissue health and function.

Prostate Health (Men)

  • Prostate Support

    Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.

  • BPH Symptoms

    May help alleviate symptoms associated with benign prostatic hyperplasia.

Anti-Aging Protocol

  • Urogenital Aging

    Part of comprehensive bioregulator protocols addressing age-related urogenital changes.

  • Tissue Regeneration

    Supports cellular regeneration in urinary and reproductive tissues.

Injectable form for subcutaneous or intramuscular administration. Standard Khavinson protocol of 10-20 day cycles, repeated 2-3 times per year for maintenance.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysSubQ or IM
Maintenance20 mg2-3 cycles yearlySubQ or IM

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water
  • Insulin syringes
  • Alcohol swabs
  • Sterile vial
  1. 1 Clean work area thoroughly
  2. 2 Reconstitute with bacteriostatic water
  3. 3 Inject water slowly down vial wall
  4. 4 Gently swirl until dissolved
  5. 5 Store refrigerated at 2-8°C
  6. 6 Use within 4 weeks of reconstitution
Prostamax

Both target prostate/urogenital health; can be combined for comprehensive support.

synergistic
Vesugen

Different targets - Vesugen for vascular, Vesilute for bladder/prostate. Can be combined.

compatible
Libidon

Complementary for male reproductive and urogenital health protocols.

synergistic
Epitalon

Often combined in comprehensive anti-aging bioregulator protocols.

compatible
Thymalin

Different target systems; no known negative interactions.

compatible
During cycle

Tissue-specific effects begin; gene expression modulation

Days 10-20

Cellular function optimization in target tissues

Post-cycle

Effects persist due to bioregulation mechanisms

Long-term

Cumulative benefits with regular cycling; tissue health maintenance

Common Side Effects

  • Generally well-tolerated
  • Injection site reactions (mild, if injectable)
  • Minimal reported side effects

Stop Signs - Discontinue if:

  • Signs of allergic reaction
  • Unusual urinary symptoms
  • Unexpected changes in urination patterns

Contraindications

  • Known hypersensitivity to peptide components
  • Active urinary tract infection (treat first)
  • Pregnancy or breastfeeding
  • Prostate cancer (consult physician)

Good Signs

  • White to off-white lyophilized powder
  • Clear solution after reconstitution
  • Certificate of analysis available
  • Proper packaging and storage

Warning Signs

  • Unknown source or unverified purity

Bad Signs

  • Discolored powder
  • Cloudy or particulate solution
  • Damaged packaging
  • Khavinson Bioregulator Peptides: Organ-Specific Effects
    St. Petersburg Institute of Bioregulation and Gerontology

    Vesilute (ED dipeptide) targets bladder and urinary tract tissues with bioregulatory effects.

  • Short Peptides and Urogenital Function
    Russian Medical Research

    ED dipeptide influences smooth muscle and vascular function in urogenital tissues.

  • Bioregulators in Anti-Aging Medicine
    Khavinson VKh et al.
    Advances in Gerontology

    Organ-specific peptide bioregulators including Vesilute support tissue-specific regeneration.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.